ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

Antonarakis Emmanuel S*; Luber Brandon; Wang Hao; Isaacs William B; Luo Jun*; Antonarakis Emmanuel S; Lu Changxue; Liang Chao; Chen Yan; Silberstein John L; Piana Danilo; Isaacs William B; Luo Jun; Lai Zhao; Chen Yidong; Chen Yidong; Antonarakis ES*; Luo J*; Antonarakis ES; Luo J
European Urology2018-8DOI: 10.1016/j.eururo.2018.01.035
2被引21阅读
引用收藏
分享

摘要

Background: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood.
Objective: To investigate the clinical significance of germlineDNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations.
Design, setting, and participants: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide.
Outcome measurements and statistical analysis: We assessed the impact of germline DNA-repair gene mutation status on >= 50% and >= 90% PSA responses, PSA progression-free survival (PSA-PFS), clinical/radiologic progression-free survival (PFS), and overall survival (OS). Survival outcomes were adjusted using propensity score-weighted multivariable Cox regression analyses.
Results and limitations: Among 172 mCRPC patients included, germline mutations (in any DNA-repair gene) were found in 12% (22/172) of men, and germline BRCA/ATM mutations specifically in 5% (9/172) of men. In unadjusted analyses, outcomes to first-line NHT were better in men with germline BRCA/ATM mutations (vs no mutations) with respect to PSA-PFS (hazard ratio [HR] 0.47; p = 0.061), PFS (HR 0.50; p = 0.090), and OS (HR 0.28; p = 0.059). In propensity score-weighted multivariable analyses, outcomes were superior in menwith germline BRCA/ATM mutations with respect to PSA-PFS (HR 0.48, 95% confidence interval [CI] 0.25-0.92; p = 0.027), PFS (HR 0.52, 95% CI 0.28-0.98; p = 0.044), and OS (HR 0.34, 95% CI 0.12-0.99; p = 0.048), but not in men with non-BRCA/ATM germline mutations (all p > 0.10). These results require prospective validation, and our conclusions are limited by the small number of patients (n = 9) with BRCA/ATM mutations.
Conclusions: Outcomes to first-line NHT appear better in mCRPC patients harboring germline BRCA/ATM mutations (vs no mutations), but not for patients with other non-BRCA/ATM germline mutations.
Patient summary: Patients with metastatic castration-resistant prostate cancer and harboring germline mutations in BRCA1/2 and ATM benefit from treatment with abiraterone and enzalutamide.

学科与关键词

关键词
DNA repairGermlineMutationAbirateroneEnzalutamide
相关
加载中…
  • Germline and somatic DNA repair gene alterations in prostate cancer
    Marc A. Dall’Era MD; John D. McPherson PhD; Allen C. Gao MD, PhD; Ralph W. DeVere White MD; Jeffrey P. Gregg MD; Primo N. Lara Jr MDCancer, 2020, 126(13): 2980-2985.被引 19
  • Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients
    Junlong Wu; Yu Wei; Jian Pan; Shengming Jin; Weijie Gu; Hualei Gan; Yao Zhu; Ding Wei YeInternational Journal of Cancer, 2021, 148(3).
  • Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
    Manish Kohli; Winston Tan; Tiantian Zheng; Amy Wang; Carlos Montesinos; Calven Wong; Pan Du; Shidong Jia; Siddhartha Yadav; Lisa G. Horvath; Kate L. Mahon; Edmond M. Kwan; Heidi Fettke; Jianjun Yu; Arun A. AzadEBioMedicine, 2020, 54: 102728.
查看全部 →

发表信息

论文状态
公开发表
期刊
European Urology
发表日期
2018-08
卷期
第 74 卷, 第 2 期
页码
218-225
DOI
10.1016/j.eururo.2018.01.035
语言
ENGLISH
期刊等级
Q1
成果收录
CHINAJOURNAL · SCI
资助标注
National Institutes of Health [R01 CA185297, P30 CA006973]; Department of Defense Prostate Cancer Research Program [W81XWH-15-2-0050, W81XWH-12-1-0605]; Commonwealth Fund; Johns Hopkins Prostate SPORE Grant [P50 CA058236]; Patrick C. Walsh Fund; Prostate Cancer Foundation

作者

  • A

    Antonarakis Emmanuel S (通讯) (第一作者)

  • L

    Luber Brandon

查看全部 20 位作者收起作者
  • W

    Wang Hao

  • I

    Isaacs William B

  • L

    Luo Jun (通讯)

  • A

    Antonarakis Emmanuel S

  • L

    Lu Changxue

  • L

    Liang Chao

  • C

    Chen Yan

  • S

    Silberstein John L

  • P

    Piana Danilo

  • I

    Isaacs William B

  • L

    Luo Jun

  • L

    Lai Zhao

  • C

    Chen Yidong

  • C

    Chen Yidong

  • A

    Antonarakis ES (通讯)

  • L

    Luo J (通讯)

  • A

    Antonarakis ES

  • L

    Luo J

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417